The association between metabolic syndrome and vascular endothelial dysfunction in adolescents

Wei,Ying; Liu,Geli; Yang,Jingyan; Zheng,Rongxiu; Jiang,Lihong; Bao,Pengli

doi:10.3892/etm.2013.1055

The association between metabolic syndrome and vascular endothelial dysfunction in adolescents

Authors:
- Ying Wei
- Geli Liu
- Jingyan Yang
- Rongxiu Zheng
- Lihong Jiang
- Pengli Bao
View Affiliations

Affiliations: Department of Pediatrics, General Hospital of Tianjin Medical University, Tianjin 300052, P.R. China
Published online on: April 9, 2013 https://doi.org/10.3892/etm.2013.1055
Pages: 1663-1666

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the association between metabolic syndrome (MS) and vascular endothelial cell dysfunction (ECD) in adolescents. Sixty obese pediatric inpatients at the General Hospital of Tianjin Medical University from February 2011 to February 2012 were included. Among these, 30 patients were obese and 30 patients were diagnosed with MS. Thirty healthy subjects were randomly selected as the control group. A series of indices, including height, body weight, waist circumference, hip circumference, waist/hip circumference and body mass index (BMI), as well as total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels were evaluated. von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) levels were determined using an enzyme linked immunosorbent assay (ELISA). Correlation analysis between height, body weight, waist circumference, hip circumference, waist/hip circumference, BMI, TC, TG, LDL, HDL and PAI-1, as well as vWF was performed. Significant increases of vWF and PAI-1 levels were observed in the MS group compared with the control group (P<0.05). For the adolescents in the obese group, a significant increase of PAI-1 level was observed compared with the control group (P<0.05). No significant difference was observed between the vWF levels in the obese and control groups. PAI-1 was positively associated with BMI, waist circumference, waist/hip circumference, TC, TG, LDL, fasting plasma glucose (FPG), fasting insulin (FINS), systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively (P<0.05). In addition, PAI-1 was negatively associated with HDL levels (P<0.05). PAI-1 and vWF may be used as biomarkers for the diagnosis of ECD. ECD in individuals with MS may be associated with obesity, blood fat, blood sugar and blood pressure. FPG, TC and TG may be risk factors for ECD.

View Figures

View References

1.	Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285:2486–2497. 2001. View Article : Google Scholar
2.	Lim HS, Lip GY and Blann AD: Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J Clin Endocrinol Metab. 89:5377–5381. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Blann AD, Naqvi T, Waite M and McCollum CN: von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens. 7:107–111. 1993.PubMed/NCBI
4.	Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG and Lip GY: Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens. 16:11–20. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Thompson SG, Kienast J, Pyke SD, Haverkate F and van de Loo C; European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:635–641. 1995. View Article : Google Scholar : PubMed/NCBI
6.	Meigs JB, Mittleman MA, Nathan DM, et al: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 283:221–228. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Alessi MC and Juhan-Vague I: PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 26:2200–2207. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Pi-Sunyer FX: Obesity: criteria and classification. Proc Nutr Soc. 59:505–509. 2000. View Article : Google Scholar : PubMed/NCBI
9.	Zimmet P, Alberti G, Kaufman F, et al: The metabolic syndrome in children and adolescents. Lancet. 369:2059–2061. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Cook S, Weitzman M, Auinger P, Nguyen M and Dietz WH: Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med. 157:821–827. 2003.PubMed/NCBI
12.	Steinberger J and Daniels SR: Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation. 107:1448–1453. 2003.
13.	Hanson M and Gluckman P: Endothelial dysfunction and cardiovascular disease: the role of predictive adaptive responses. Heart. 91:864–866. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Versari D, Daghini E, Virdis A, Ghiadoni L and Taddei S: Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 32(Suppl 2): S314–S321. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Bell DM, Johns TE and Lopez LM: Endothelial dysfunction: implications for therapy of cardiovascular diseases. Ann Pharmacother. 32:459–470. 1998. View Article : Google Scholar : PubMed/NCBI
16.	Dusheiko GM: Review article: the management of hepatitis A, B, D and non-A non-B. Aliment Pharmacol Ther. 3:1–20. 1989. View Article : Google Scholar : PubMed/NCBI
17.	Binder BR, Christ G, Gruber F, et al: Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci. 17:56–61. 2002.PubMed/NCBI
18.	Huang K, Zou CC, Yang XZ, et al: Carotid intima-media thickness and serum endothelial marker levels in obese children with metabolic syndrome. Arch Pediatr Adolesc Med. 164:846–851. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Carr DB, Utzschneider KM, Hull RL, et al: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 53:2087–2094. 2004. View Article : Google Scholar
20.	Aggoun Y: Obesity, metabolic syndrome, and cardiovascular disease. Pediatr Res. 61:653–659. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Nesto RW: The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med. 4(Suppl 6): S11–S18. 2003.PubMed/NCBI
22.	Chong AY, Blann AD and Lip GY: Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM. 96:253–267. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Pinkney JH, Stehouwer CD, Coppack SW and Yudkin JS: Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 46(Suppl 2): S9–S13. 1997. View Article : Google Scholar : PubMed/NCBI
24.	Conlan MG, Folsom AR, Finch A, et al: Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 70:380–385. 1993.PubMed/NCBI
25.	Wen Y, Gu J, Li SL, et al: Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology. 147:2518–2525. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Myers JE and Baker PN: Hypertensive diseases and eclampsia. Curr Opin Obstet Gynecol. 14:119–125. 2002. View Article : Google Scholar : PubMed/NCBI